Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SCORE2-Diabetes

- PMLiVE

New research highlights mental health support gap for autoimmune disease patients

More than 1,800 patients with SARDs were surveyed for neurological and psychiatric symptoms

- PMLiVE

Eli Lilly/Boehringer’s Jardiance for children with type 2 diabetes accepted by FDA

The incidence of type 2 diabetes in children has nearly doubled over the past two decades

- PMLiVE

Esperion’s heart drug shown to reduce risk of major adverse cardiovascular events

Cardiovascular diseases result in an estimated 17.9 million deaths each year

- PMLiVE

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Rybelsus was initially approved in 2019 as a second-line treatment

- PMLiVE

Oramed’s oral insulin candidate fails to meet phase 3 targets

The company said it expects to end its oral insulin clinical activities for type 2 diabetes

- PMLiVE

First UK proton beam therapy trial launches for certain breast cancer patients

The trial will assess the therapy in patients at risk of heart problems after standard radiotherapy

- PMLiVE

ICR and University of Cambridge reveal new prostate cancer prediction tool

The new study describing the model is published in the Journal of Clinical Oncology

- PMLiVE

Lab-grown red blood cells used for human transfusions in world-first clinical trial

Manufactured blood cells could revolutionise treatments for people with blood disorders

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

Cancer Research UK scientists announce ‘breakthrough’ in understanding of metastasis

The team found that cancer cells ‘exploit’ the body’s tissue repair process to spread cells

- PMLiVE

University of Cambridge launches Early Cancer Institute for complex cancers

It is the first UK institute dedicated to identifying and researching early cancers

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links